Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …

Importance Measurable residual disease (MRD) refers to neoplastic cells that cannot be
detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia …

Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective
therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in …

Background Poly (ADP-ribose) polymerase (PARP) inhibitors have shown efficacy and
acceptable safety in a range of neoplasms, particularly in ovarian cancers. However, some …

The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

Background Leukemias are a group of life-threatening malignant disorders of the blood and
bone marrow. The incidence of leukemia varies by pathological types and among different …

Background Several important treatment and supportive care strategies have been
implemented over the past 4 decades in the management of acute myeloid leukemia (AML) …

Background Acute myeloid leukemia (AML) is a common leukemia subtype and has a poor
prognosis. The risk of AML is highly related to age. In the context of population aging, a …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …